Compare DOLE & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | ARDX |
|---|---|---|
| Founded | 1851 | 2007 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2021 | 2014 |
| Metric | DOLE | ARDX |
|---|---|---|
| Price | $14.57 | $7.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.45 |
| AVG Volume (30 Days) | 697.6K | ★ 5.3M |
| Earning Date | 02-25-2026 | 02-19-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $8,974,210,000.00 | $398,234,000.00 |
| Revenue This Year | $9.28 | $22.77 |
| Revenue Next Year | $1.84 | $28.02 |
| P/E Ratio | $97.15 | ★ N/A |
| Revenue Growth | 7.09 | ★ 58.12 |
| 52 Week Low | $12.20 | $3.21 |
| 52 Week High | $15.73 | $8.05 |
| Indicator | DOLE | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 61.79 |
| Support Level | $13.83 | $5.53 |
| Resistance Level | $14.74 | $8.05 |
| Average True Range (ATR) | 0.25 | 0.44 |
| MACD | -0.08 | 0.16 |
| Stochastic Oscillator | 52.33 | 61.11 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.